FY2030 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Alector in a note issued to investors on Friday, February 27th. HC Wainwright analyst A. Fein expects that the company will post earnings per share of ($0.58) for the year. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.05. The firm had revenue of $6.24 million for the quarter, compared to analysts’ expectations of $1.78 million. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%.

Several other research analysts also recently weighed in on ALEC. Wall Street Zen downgraded shares of Alector from a “hold” rating to a “sell” rating in a research report on Sunday. Morgan Stanley reissued an “underweight” rating on shares of Alector in a report on Thursday, January 8th. BTIG Research upgraded Alector from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alector in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.25.

Alector Stock Performance

ALEC opened at $2.11 on Monday. The firm’s fifty day simple moving average is $1.88 and its two-hundred day simple moving average is $2.03. Alector has a 52-week low of $0.87 and a 52-week high of $3.40. The company has a market cap of $232.86 million, a price-to-earnings ratio of -1.52 and a beta of 0.58. The company has a quick ratio of 3.83, a current ratio of 3.83 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On Alector

Several hedge funds and other institutional investors have recently made changes to their positions in ALEC. Bank of America Corp DE boosted its stake in Alector by 1.8% during the second quarter. Bank of America Corp DE now owns 343,909 shares of the company’s stock worth $481,000 after buying an additional 5,927 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Alector by 5.3% during the 2nd quarter. Los Angeles Capital Management LLC now owns 151,896 shares of the company’s stock worth $213,000 after acquiring an additional 7,600 shares during the period. Sio Capital Management LLC boosted its position in shares of Alector by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 845,531 shares of the company’s stock valued at $1,184,000 after acquiring an additional 8,372 shares during the last quarter. Mackenzie Financial Corp grew its holdings in shares of Alector by 3.4% in the third quarter. Mackenzie Financial Corp now owns 283,712 shares of the company’s stock valued at $840,000 after purchasing an additional 9,270 shares during the period. Finally, Lexington Partners L.P. acquired a new stake in Alector during the third quarter worth about $30,000. Institutional investors and hedge funds own 85.83% of the company’s stock.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.